RxDoctor Payments Data

Misty Hartmire

Family · Evansville, INNPI 1417206541

Payments from drug & device makers

$2,582in general payments, 2019–2025

Across 100 payments — averaging $25.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$827
  • Theratechnologies Inc.$149
  • Janssen Products, LP$142
  • Johnson & Johnson$98
  • AbbVie$70
  • plus $58 from 3 others

What the payments were for

  • Food & beverage$2,44095%
  • Education$1425%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead30$1,238
Viiv Healthcare Company50$827
Theratechnologies Inc.6$149
Janssen Products, LP2$142
Johnson & Johnson5$98
AbbVie4$70
Vyera Pharmaceuticals, LLC1$22
Merck1$20
EMD Serono, Inc.1$16

How this compares

$2,582 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$4,759
Medicare patients
19
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala212$823,001
DovatoDolutegravir Sodium/Lamivudine83$241,547
JulucaDolutegravir/Rilpivirine63$214,237
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf42$207,590
DescovyEmtricitabine/Tenofov Alafenam61$132,004
TivicayDolutegravir Sodium27$87,504
PifeltroDoravirine13$21,516
Darunavir30$14,926
OzempicSemaglutide12$13,283
VascepaIcosapent Ethyl12$4,876
Ritonavir24$3,920
MenactraMening Vac A,c,y,w-135 Dip/Pf13$2,248
Mometasone Furoate13$1,307
Gabapentin27$451
Albuterol Sulfate HfaAlbuterol Sulfate21$437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$1,238$955,005273 claims
Viiv Healthcare CompanyDovato, Juluca, Tivicay$827$543,289173 claims
Janssen Products, LPSymtuza$142$207,59042 claims
MerckPifeltro$20$21,51613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →